Lancet:按需暴露前预防在男性同性恋中预防HIV的效果、安全性以及对性行为的影响

2017-07-24 qinqiyun MedSci原创

HIV的高危人群包括:男性同性恋者、静脉吸毒者、与HIV携带者经常有性接触者、经常输血及血制品者和HIV感染母亲所生婴儿。目前尚没有有效的治疗方法,预防感染显得尤其重要。

HIV的高危人群包括:男性同性恋者、静脉吸毒者、与HIV携带者经常有性接触者、经常输血及血制品者和HIV感染母亲所生婴儿。目前尚没有有效的治疗方法,预防感染显得尤其重要。目前缺乏关于按需暴露前预防(PrEP)的数据。7月23日Lancet上发表了一篇关于其在性行为上的有效性、安全性和影响的队列研究的文章。研究人员招募异性恋的女性和同性恋的男性,在7个不同地方进行一随机化、安慰剂为对照的ANRS IPERGAY试验,然后进行开放性标签的扩展试验,试验组按需在性行为前后服用300mg富马酸替诺福韦酯和200mg恩曲他滨。然后评估HIV和其他性传播性疾病(STIs)的发病率、PrEP的持续性、安全性和性行为。用多种统计学方法处理相关数据。2014年11月4日-2015年1月27日,共招募361位参与者。随访中位时间是18.4个月(IQR 17.7-19.1)。一位参与者因感染HIV未持续PrEP。HIV的发病率是0.19/百人·年(95% CI 0.01-1.08),对照组是6.60/百人·年(3.60-11.05),提示按需性PrEP可降低HIV感染率的97%(95% CI 81-100)

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1829102, encodeId=d5d31829102ed, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Dec 30 07:57:00 CST 2017, time=2017-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1322366, encodeId=de991322366f0, content=<a href='/topic/show?id=cde152e227a' target=_blank style='color:#2F92EE;'>#性行为#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52722, encryptionId=cde152e227a, topicName=性行为)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e1c493, createdName=xugc, createdTime=Tue Jul 25 23:57:00 CST 2017, time=2017-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350132, encodeId=413713501325b, content=<a href='/topic/show?id=81ea3894939' target=_blank style='color:#2F92EE;'>#同性恋#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38949, encryptionId=81ea3894939, topicName=同性恋)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Jul 25 23:57:00 CST 2017, time=2017-07-25, status=1, ipAttribution=)]
    2017-12-30 howi
  2. [GetPortalCommentsPageByObjectIdResponse(id=1829102, encodeId=d5d31829102ed, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Dec 30 07:57:00 CST 2017, time=2017-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1322366, encodeId=de991322366f0, content=<a href='/topic/show?id=cde152e227a' target=_blank style='color:#2F92EE;'>#性行为#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52722, encryptionId=cde152e227a, topicName=性行为)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e1c493, createdName=xugc, createdTime=Tue Jul 25 23:57:00 CST 2017, time=2017-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350132, encodeId=413713501325b, content=<a href='/topic/show?id=81ea3894939' target=_blank style='color:#2F92EE;'>#同性恋#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38949, encryptionId=81ea3894939, topicName=同性恋)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Jul 25 23:57:00 CST 2017, time=2017-07-25, status=1, ipAttribution=)]
    2017-07-25 xugc
  3. [GetPortalCommentsPageByObjectIdResponse(id=1829102, encodeId=d5d31829102ed, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Dec 30 07:57:00 CST 2017, time=2017-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1322366, encodeId=de991322366f0, content=<a href='/topic/show?id=cde152e227a' target=_blank style='color:#2F92EE;'>#性行为#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52722, encryptionId=cde152e227a, topicName=性行为)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e1c493, createdName=xugc, createdTime=Tue Jul 25 23:57:00 CST 2017, time=2017-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350132, encodeId=413713501325b, content=<a href='/topic/show?id=81ea3894939' target=_blank style='color:#2F92EE;'>#同性恋#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38949, encryptionId=81ea3894939, topicName=同性恋)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Jul 25 23:57:00 CST 2017, time=2017-07-25, status=1, ipAttribution=)]